Goethe-Universität Frankfurt am Main

LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER (FMF) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY (2022) Henes J, Kuemmerle-Deschner JB, Krickau T, Kallinich T, Dressler F, Horneff G, Meier F, et al. Conference contribution Pathologic response after induction chemo-immunotherapy with single or double immune checkpoint inhibition in locally advanced head and neck squamous cell carcinoma (HNSCC): Expansion cohorts of the CheckRad-CD8 trial. (2022) Hecht M, Eckstein M, Kallies A, Klautke G, Illmer T, von der Grün J, Laban S, et al. Conference contribution COMPARISON OF PATIENTS WITH AXIAL PSA AND PATIENTS WITH AXSPA AND CONCOMITANT PSORIASIS (2022) Regierer A, Weiss A, Baraliakos X, Behrens F, Poddubnyy D, Schett G, Lorenz HM, et al. Conference contribution Hereditary Muscle diseases (2022) Fujak A, Forst R, Forst J Journal article Decision Conflicts in Clinical Care during COVID-19: A Patient Perspective (2022) Haier J, Beller J, Adorjan K, Bleich S, De Greck M, Griesinger F, Hein A, et al. Journal article Generalisierte pustulöse Psoriasis: Überblick zum Status quo und Ergebnisse einer Diskussionsrunde (2022) Reich K, Augustin M, Gerdes S, Ghoreschi K, Kokolakis G, Mößner R, Mrowietz U, et al. Journal article, Review article F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial (2022) Beck M, Hartwich J, Eckstein M, Schmidt D, Gostian AO, Müller-Hübner SKU, Rutzner S, et al. Journal article The Architecture of a Feasibility Query Portal for Distributed COVID-19 Fast Healthcare Interoperability Resources (FHIR) Patient Data Repositories: Design and Implementation Study (2022) Gründner J, Deppenwiese N, Folz M, Koehler T, Kroll B, Prokosch HU, Rosenau L, et al. Journal article Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B (2022) Furlanetto J, Marme F, Thode C, Nekljudova V, Liu Y, Jimenez MM, Reimer T, et al. Conference contribution Intermediate biopsies during neoadjuvant chemotherapy for breast cancer to predict patient outcome (2022) Sinn BV, Untch M, Karn T, Van Mackelenbergh M, Huober J, Sychra K, Schmitt WD, et al. Conference contribution